NCT04195919View on ClinicalTrials.gov

The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

May 24, 2021

Study Completion Date

May 24, 2021

Conditions
Hemodialysis Patients
Interventions
DRUG

Evogliptin 5mg

Participants receive Single oral administration of Evogliptin 5mg on day1

DRUG

Evogliptin 5mg

"Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis)~Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period"

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT04195919 - The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients | Biotech Hunter | Biotech Hunter